Avandia (rosiglitazone) increases the risk of heart attack

June 2007

Patients are asking about the news that Avandia (rosiglitazone) increases the risk of heart attack.

A new meta-analysis suggests a higher risk of heart attacks in patients taking rosiglitazone compared to other meds or placebo.

Experts crunching the same numbers come up with differing conclusions, and point out the study's shortcomings. The complicated statistics are explored in our Detail-Document.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote